Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Dec 6, 2019
Posted in: News, Press & Media

Home » Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Dec 6, 2019
Posted in: News, Press & Media

Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent

November 5, 2025

FDA Submission of IND for MagSense® HER2 Phase 2 Clinical Trial on Track Q4 2025 Key Highlights: Wayne State University Collaboration Program Delivers Positive and

[Video] The Market Bull – Imagion Biosystems’ Magsense Non-invasive Cancer Detection

October 24, 2025

Video transcript: Advances in treatment for cancer have greatly improved survivability when the cancer is caught early. However, despite global spending of over $100

Imagion Biosystems to present at next Emerging Growth Conference

October 22, 2025

MIAMI, FL — Miami-based Emerging Growth has invited medical-imaging company Imagion Biosystems (ASX: IBX) to present at the next Emerging Growth Conference on October 23,

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Imagion Non-Executive Director Mike Harsh tracks the history of imaging technologies

Related Articles

Positive Results Received from WSU on MagSense® Dosage – Phase 2 Clinical Trial on HER2 Breast Cancer Imaging Agent

[Video] The Market Bull – Imagion Biosystems’ Magsense Non-invasive Cancer Detection

Imagion Biosystems to present at next Emerging Growth Conference

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list